Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 3-Year ROIIC % is 27.99 as of Dec. 2025, which is 17% above its 10-year median of 23.87. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 70.59% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
WuXi XDC Cayman's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 27.99%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for WuXi XDC Cayman's 3-Year ROIIC % or its related term are showing as below:
STU:L74's 3-Year ROIIC % is ranked better than 70.59% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.385
vs STU:L74: 27.99
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
WuXi XDC Cayman 3-Year ROIIC % Related Terms
WuXi XDC Cayman 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L74 vs TMO, DHR, NTRA: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
WuXi XDC Cayman (STU:L74) has a 3-Year ROIIC % of 27.99 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on WuXi XDC Cayman and its competitors. This is 17% above median its historical median of 23.87. Over the past decade, WuXi XDC Cayman's 3-Year ROIIC % has ranged from 19.13 to 27.99. According to the industry distribution chart, WuXi XDC Cayman ranks #60 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 29.4%.
Is WuXi XDC Cayman's 3-Year ROIIC % too high?
WuXi XDC Cayman's current 3-Year ROIIC % of 27.99 is 17% above median its 10-year median of 23.87. Over the past 10 years, this metric has ranged from a low of 19.13 to a high of 27.99. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.39. WuXi XDC Cayman's value of 27.99 is 7170.1% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #60 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #60 out of 204 companies for 3-Year ROIIC %. This puts WuXi XDC Cayman in the upper half of its industry. The industry median 3-Year ROIIC % is 0.39. WuXi XDC Cayman's value of 27.99 is 7170.1% above this benchmark. Historically, WuXi XDC Cayman's own 3-Year ROIIC % has ranged from 19.13 to 27.99 over the past decade. While the company's 10-year median is 23.87 vs. the industry median of 0.39, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.39, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current 3-Year ROIIC % of 27.99 is 7170.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current 3-Year ROIIC % is 27.99, which is 17% above median its own 10-year median of 23.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current 3-Year ROIIC % of 27.99. The current 3-Year ROIIC % is 27.99, which is 17% above median its 10-year median of 23.87 and 7170.1% above the Medical Diagnostics & Research industry median of 0.39. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current 3-Year ROIIC % is 27.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
